featured
Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab–Ipilimumab Therapy in Patients With Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Network Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
JAMA Netw Open 2023 Jun 01;6(6)e2319607, M Gupta, I Stukalin, D Meyers, S Goutam, DYC Heng, T Cheng, J Monzon, V NavaniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.